Immunotherapy: Primed for a response

Nature Reviews Cancer

Volumn 15, Issue 5, 2015, Pages 258-259

  Seton Rogers, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; DIPHTHERIA TETANUS TOXOID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OVALBUMIN; TETANUS TOXOID;

CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CELL MIGRATION; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; ISCHEMIC PRECONDITIONING; NONHUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; DENDRITIC CELL; DRUG EFFECTS; FEMALE; IMMUNOLOGY;

ANIMALS; CANCER VACCINES; CHEMOKINE CCL3; DENDRITIC CELLS; FEMALE; GLIOBLASTOMA; HUMANS; TETANUS TOXOID;

EID: 84928581410     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3945     Document Type: Note

References (1)

1. Mitchell, D. A. & Batich, K. A. et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519, 366-369 (2015)